At the University of Maryland, College Park, about 35 smokers are trying to liberate themselves from nicotine by reducing the buzz it gives them, testing a “quit smoking” vaccine.

Forty percent of participants have quit so far during the ongoing study using the vaccine, NicVAX, and 9 percent quit on a placebo in preliminary studies, the largest differential ever, according to Tom Rathjem, vice president of investor relations for Nabi Biopharmaceuticals, the furthest along of three companies developing the revolutionary vaccine.

Recommended Stories

The FDA’s new tobacco plan leaves much room for improvement

FDA embraces sanity with new approach to vaping

FDA plans 95% reduction in nicotine for cigarettes